• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial.

作者信息

Hamadani Mehdi, Spira Alexander, Zhou Xiaolei, Liao Laura, Chen Lei, Radford John, Ai Weiyun, Solh Melhem, Ardeshna Kirit M, Hess Brian, Caimi Paolo F, Stathis Anastasios, Carlo-Stella Carmelo, Alderuccio Juan Pablo, Kahl Brad, Wang Ying, Qin Yajuan, Xu Zhiying Cindy, Zinzani Pier Luigi

机构信息

Division of Hematology and Oncology, BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI.

Virginia Cancer Specialists Research Institute, Fairfax, VA.

出版信息

Blood Adv. 2024 Jan 9;8(1):93-98. doi: 10.1182/bloodadvances.2023010636.

DOI:10.1182/bloodadvances.2023010636
PMID:37871303
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC10787240/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d8/10787240/da8c468896d6/BLOODA_ADV-2023-010636-gr1ab.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d8/10787240/da8c468896d6/BLOODA_ADV-2023-010636-gr1ab.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89d8/10787240/da8c468896d6/BLOODA_ADV-2023-010636-gr1ab.jpg

相似文献

1
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial.在LOTIS-2临床试验中接受loncastuximab tesirine治疗的老年和年轻患者的临床结局。
Blood Adv. 2024 Jan 9;8(1):93-98. doi: 10.1182/bloodadvances.2023010636.
2
Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma.洛卡妥昔单抗：一种治疗复发或难治性弥漫性大B细胞淋巴瘤的有效疗法。
Eur J Clin Pharmacol. 2022 May;78(5):707-719. doi: 10.1007/s00228-021-03253-3. Epub 2022 Jan 21.
3
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.Loncastuximab tesirine 治疗复发或难治性弥漫性大 B 细胞淋巴瘤（LOTIS-2）：一项多中心、开放标签、单臂、2 期临床试验。
Lancet Oncol. 2021 Jun;22(6):790-800. doi: 10.1016/S1470-2045(21)00139-X. Epub 2021 May 11.
4
Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.评估 loncastuximab tesirine 注射液治疗复发或难治性大 B 细胞淋巴瘤成人患者的疗效和安全性。
Expert Rev Anticancer Ther. 2021 Dec;21(12):1313-1320. doi: 10.1080/14737140.2021.1988853. Epub 2021 Oct 17.
5
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study.洛纳妥昔单抗替西瑞林治疗复发/难治性高级别B细胞淋巴瘤：来自LOTIS-2研究的亚组分析
Blood Adv. 2022 Aug 23;6(16):4736-4739. doi: 10.1182/bloodadvances.2022007782.
6
Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Loncastuximab Tesirine 治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者的健康相关生活质量、症状和耐受性。
Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):158-168. doi: 10.1016/j.clml.2021.09.001. Epub 2021 Sep 22.
7
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.ADCT-402（Loncastuximab Tesirine）治疗复发/难治性 B 细胞非霍奇金淋巴瘤的 I 期研究，Loncastuximab Tesirine 是一种新型的吡咯苯并二氮杂卓类抗体药物偶联物。
Clin Cancer Res. 2019 Dec 1;25(23):6986-6994. doi: 10.1158/1078-0432.CCR-19-0711. Epub 2019 Nov 4.
8
Loncastuximab tesirine for diffuse large B-cell lymphoma.Loncastuximab tesirine 用于弥漫性大 B 细胞淋巴瘤。
Drugs Today (Barc). 2021 Dec;57(12):733-743. doi: 10.1358/dot.2021.57.12.3352741.
9
Loncastuximab Tesirine: First Approval.朗斯妥昔单抗：首次获批。
Drugs. 2021 Jul;81(10):1229-1233. doi: 10.1007/s40265-021-01550-w.
10
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.Loncastuximab tesirine 治疗复发/难治性 B 细胞非霍奇金淋巴瘤的 1 期研究的最终结果。
Blood. 2021 May 13;137(19):2634-2645. doi: 10.1182/blood.2020007512.

引用本文的文献

1
Treatment of Secondary Hemophagocytic Lymphohistiocytosis Associated With Diffuse Large B-cell Lymphoma Using Loncastuximab Tesirine As Lymphoma-Directed Therapy.使用loncastuximab tesirine作为淋巴瘤导向治疗方案治疗与弥漫性大B细胞淋巴瘤相关的继发性噬血细胞性淋巴组织细胞增生症
Cureus. 2024 Sep 29;16(9):e70450. doi: 10.7759/cureus.70450. eCollection 2024 Sep.
2
Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Loncastuximab Tesirine 治疗复发或难治性弥漫性大 B 细胞淋巴瘤。
Int J Mol Sci. 2024 Jul 10;25(14):7580. doi: 10.3390/ijms25147580.
3
A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers.

本文引用的文献

1
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.阿基仑赛注射液对比标准治疗用于 65 岁及以上复发/难治性大 B 细胞淋巴瘤患者的安全性和有效性。
Clin Cancer Res. 2023 May 15;29(10):1894-1905. doi: 10.1158/1078-0432.CCR-22-3136.
2
Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience.年龄对大B细胞淋巴瘤CAR-T细胞疗法疗效的影响：GLA/DRST的经验
Bone Marrow Transplant. 2023 Feb;58(2):229-232. doi: 10.1038/s41409-022-01867-4. Epub 2022 Nov 22.
3
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data.
FDA 批准的抗体药物偶联物在人类癌症中的临床疗效评价。
Mol Cancer. 2024 Mar 23;23(1):62. doi: 10.1186/s12943-024-01963-7.
洛纳妥昔单抗替西瑞林治疗复发或难治性弥漫性大B细胞淋巴瘤：临床数据综述
Ther Adv Hematol. 2022 Mar 22;13:20406207221087511. doi: 10.1177/20406207221087511. eCollection 2022.
4
Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Loncastuximab Tesirine 治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者的健康相关生活质量、症状和耐受性。
Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):158-168. doi: 10.1016/j.clml.2021.09.001. Epub 2021 Sep 22.
5
Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study.弥漫性大 B 细胞淋巴瘤诊断 1 年后幸存者的生活质量：LYSA 研究。
Ann Hematol. 2022 Feb;101(2):317-332. doi: 10.1007/s00277-021-04689-4. Epub 2021 Oct 6.
6
Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.评估 loncastuximab tesirine 注射液治疗复发或难治性大 B 细胞淋巴瘤成人患者的疗效和安全性。
Expert Rev Anticancer Ther. 2021 Dec;21(12):1313-1320. doi: 10.1080/14737140.2021.1988853. Epub 2021 Oct 17.
7
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.Loncastuximab tesirine 治疗复发或难治性弥漫性大 B 细胞淋巴瘤（LOTIS-2）：一项多中心、开放标签、单臂、2 期临床试验。
Lancet Oncol. 2021 Jun;22(6):790-800. doi: 10.1016/S1470-2045(21)00139-X. Epub 2021 May 11.
8
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.老年弥漫大 B 细胞淋巴瘤患者管理中的挑战与机遇。
Oncologist. 2021 Feb;26(2):120-132. doi: 10.1002/onco.13610. Epub 2020 Dec 9.
9
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.侵袭性 B 细胞非霍奇金淋巴瘤患者在强化一线治疗失败后的结局。
Cancer. 2020 Jan 15;126(2):293-303. doi: 10.1002/cncr.32526. Epub 2019 Sep 30.
10
Investigating Potential Bias in Patient-Reported Outcomes in Open-label Cancer Trials.调查开放标签癌症试验中患者报告结局的潜在偏倚。
JAMA Oncol. 2019 Apr 1;5(4):457-458. doi: 10.1001/jamaoncol.2018.6205.